Akari Therapeutics (AKTX) Common Equity (2011 - 2026)

Akari Therapeutics (AKTX) has reported Common Equity for 16 consecutive years, with $14.4 million the latest figure, recorded in Q1 2026.

• Quarterly Common Equity fell 33.87% year-over-year to $14.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $14.4 million (down 33.87% YoY) and the FY2025 annual result came in at $28.3 million, up 27.44% from the prior year.
• Common Equity fell to $14.4 million in Q1 2026 per AKTX's latest filing, from $28.3 million in the prior quarter.
• Over the last five years, Common Equity for AKTX reached as high as $28.3 million in Q4 2025 and fell as low as -$6.7 million in Q3 2024.
• A 5-year average of $9.4 million and a median of $6.6 million in 2023 frame the typical range for Common Equity.
• The largest YoY upside for Common Equity was 9806.99% in 2024 against a maximum downside of 3242.72% in 2024.
• Year by year, Common Equity stood at $1.8 million in 2022, then tumbled by 112.79% to -$229000.0 in 2023, then jumped by 9806.99% to $22.2 million in 2024, then rose by 27.44% to $28.3 million in 2025, then slumped by 49.24% to $14.4 million in 2026.
• According to Business Quant data, Common Equity over the past three periods registered $14.4 million, $28.3 million, and $22.7 million for Q1 2026, Q4 2025, and Q3 2025 respectively.